Image Source: AsiaOne
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms Medicine in Drug Discovery Publication Explores Combination Protein Therapeutics, Including BET Inhibitors, in Preventing Severe Organ Damage from COVID-19 and Reviews Potential Treatments GlobeNewswire October 26, 2020 CALGARY, Alberta, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its late-stage clinical candidate, apabetalone, has been prominently featured in a recent article, titled: “Protein-driven mechanism of multiorgan damage in COVID-19”, in the peer-reviewed journal Medicine in Drug Discovery.
Source: AsiaOne